Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.34 |
| ▸ | FAP | Q12884 | 2/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6563452 | 0.99 | DPP4 (0.33) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL7378319 | 0.85 | DPP4 (0.36) | DPP4DPP7FAPPREPDPP8 | |
| Hydrochloric Acid SCHEMBL6338693 | 0.84 | DPP4 (0.35) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL6774749 | 0.80 | MAPT (0.33) | DPP4FAPPREPDPP8DPP9 | |
| SCHEMBL27698272 | 0.74 | NPSR1 (0.33) | MAPT | |
| SCHEMBL6780059 | 0.73 | DPP4 (0.32) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL6980673 | 0.72 | — | — | |
| SCHEMBL31367709 | 0.66 | ATM (0.35) | — | |
| SCHEMBL25435975 | 0.64 | NR1I2 (0.34) | — | |
| SCHEMBL25435979 | 0.64 | NR1I2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774110-B2 | ANTITHROMBOTIC ACTIVITY AND HIGH ORAL BIOAVAILABILITY; E.G. N-AMINOSULFONYL-D-DIPHENYLALANYL-L-PROLYL-((4-AMIDINOPHENYL)METHYL)AMIDE | LG LIFE SCIENCES LTD. (KR) | 2004-08-10 | — | — | US | disclosed |
| US-20020169113-A1 | Orally available peptidic thrombin inhibitors | LG LIFE SCIENCES LTD. (KR) | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169113-A1 | Orally available peptidic thrombin inhibitors | F2, SERPINC1, TFPI | DPP4 107/4885DPP7 84/4885FAP 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.